GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
DPA International on MSN12d
British pharmaceutical company GSK reports drop in Q3 pre-tax profitBritish pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...
Bearish flow noted in GSK (GSK) Pharma with 14,964 puts trading, or 17x expected. Most active are 11/1 weekly 37 puts and 11/1 weekly 38.5 calls, with total volume in those strikes near 19,700 ...
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.
GSK shares were down 3.9%, as of 0958 GMT, after earlier hitting their lowest since November 2023. Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global ...
The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...
The Wall Street Journal on MSN12d
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine DemandGSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback